COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00348400
Recruitment Status : Completed
First Posted : July 4, 2006
Last Update Posted : June 1, 2007
Information provided by:
Innovative Medical

Brief Summary:
Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy

Condition or disease Intervention/treatment Phase
Glaucoma Drug: Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Official Title: Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • · Male or female > 18 years of age

    • Diagnosis of open-angle glaucoma or ocular hypertension
    • IOP > 16 mm Hg in each eye at the latanoprost -treated baseline evaluation
    • Presently on latanoprost monotherapy for at least 6 weeks
    • Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

  • · Known contraindication or allergy to brimonidine or any of its components

    • Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2%
    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator.
    • Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed).
    • Corneal abnormalities
    • History of intraocular surgery within the last 3 months
    • Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control
    • Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00348400

Layout table for location information
United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Innovative Medical
Layout table for investigator information
Principal Investigator: Robert Noecker, MD UPMC Eye Center
Layout table for additonal information Identifier: NCT00348400    
Other Study ID Numbers: 5099
First Posted: July 4, 2006    Key Record Dates
Last Update Posted: June 1, 2007
Last Verified: May 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Ocular Hypertension
Eye Diseases
Brimonidine Tartrate
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors